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Abstract 
Background: The role of an episode of acute kidney injury (AKI) in long‑term mortality among initial survivors of criti‑
cal illness is controversial. We aimed to determine whether AKI is independently associated with decreased survival at 
3 years among 30‑day survivors of intensive care.
Results: We included 2336 30‑day survivors of intensive care enrolled in the FINNAKI study conducted in seventeen 
medical–surgical ICUs in Finland during a 5‑month period in 2011–2012. The incidence of AKI, defined by the Kidney 
Disease: Improving Global Outcomes criteria, was 34.6%, and 192 (8.3%) commenced RRT. The 3‑year mortality among 
AKI patients was 23.5% (95% CI 20.6–26.4%) compared to 18.9% (17.0–20.9%) of patients without AKI, p = 0.01. 
However, after adjustments using Cox proportional hazards regression, AKI was not associated with decreased 3‑year 
survival (HR 1.05; CI 95% 0.86–1.27), whereas advanced age, poor pre‑morbid functional performance, and presence 
of several comorbidities were. Additionally, we matched AKI patients to non‑AKI patients 1:1 according to age, gender, 
presence of severe sepsis, and a propensity score to develop AKI. In the well‑balanced matched cohort, 3‑year mortal‑
ity among AKI patients was 136 of 662 (20.5%; 17.5–23.6%) and among matched non‑AKI patients 143 of 662 (21.6%; 
18.5–24.7%), p = 0.687. Neither AKI nor RRT was associated with decreased survival at 3 years in the sensitivity analy‑
ses that excluded patients (1) with chronic kidney disease, (2) with AKI not commenced renal replacement therapy 
(RRT), and (3) with estimated pre‑admission creatinine, chronic kidney disease, or AKI stage 1.
Conclusion: AKI was not an independent risk factor for 3‑year mortality among 30‑day survivors. Increased 3‑year 
mortality among patients with AKI who survive critical illness may not be related to AKI per se, but rather to advanced 
age and pre‑existing comorbidities.
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Background
Acute kidney injury (AKI) is a frequently encountered 
syndrome in the critically ill, with an incidence varying 
from 15% up to 40% [1–5]. AKI can markedly increase 
the severity of acute illness [5, 6] as well as the length 
of intensive care unit (ICU) and hospital stay [1, 2, 5, 6]. 
Moreover, patients with AKI are susceptible to the later 
development of chronic kidney disease (CKD) [4, 7].
AKI has been significantly associated with increased 
short-term mortality [3, 4, 6, 8], but results about its 
impact on increased long-term mortality among initial 
survivors of AKI and critical illness are few and conflict-
ing. A large cohort study revealed the 1-year mortal-
ity of 30-day survivors of AKI defined by RIFLE (risk, 
injury, failure, loss, end-stage renal disease) creatinine 
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(Cr) criteria to range from 20.5 to 23.8% with increas-
ing severity of AKI, compared to 10.7% of the patients 
without AKI [5]. A 10-year follow-up study among criti-
cally ill patients found stage 1 AKI patients to have worse 
crude survival rate than patients without AKI [9]. The 
difference was significant also among 28-day survivors, 
but became nonsignificant after adjusting for confound-
ers [9]. Additionally, 30-day survivors commenced renal 
replacement therapy (RRT) did not have worse 3-year 
outcome compared to their propensity-matched control 
group of hospitalized patients without AKI [10]. Moreo-
ver, among all ICU patients, the short-term mortality has 
been related mostly to the type and severity of acute ill-
ness, whereas long-term mortality among initial survi-
vors has been primarily determined by patient age and 
comorbidities [11], which are also well-known predispos-
ing factors for the development of AKI [1].
Thus, we hypothesized that critically ill patients with 
AKI have decreased long-term survival compared to 
patients without AKI, but that pre-existing comorbidities 
and advanced age could be explanatory factors. There-
fore, in this analysis among 30-day survivors of intensive 
care, we aimed to determine whether AKI is indepen-
dently associated with increased 3-year mortality.
Methods
We performed a prospective cohort study in 17 ICUs 
in Finland between September 1, 2011, and February 1, 
2012 [3]. The Ethics Committee of the Department of 
Surgery at Helsinki University Hospital gave approval for 
the study protocol and the use of deferred consent with 
written informed consent obtained from the patient or 
proxy as soon as possible. The Finnish National Insti-
tute of Health and Welfare approved collection of data 
of deceased patients from medical records if an informed 
consent could not be obtained.
Patients
All adult (>18 years) patients with an emergency admis-
sion to the study ICUs of any duration, or an elective 
admission expecting to last over 24  h, were included 
to this Finnish Acute Kidney Injury (FINNAKI) study 
[3]. Patients who (1) were on chronic dialysis, (2) were 
readmitted and had received RRT during their previous 
admission, (3) were organ donors, (4) had insufficient 
language skills for giving informed consent or were not 
permanent Finnish residents, (5) were transferred from 
another ICU and had already been included for the study 
data collection period of five days, or (6) who were inter-
mediate care patients were excluded from the study. We 
followed the 2901 included patients [3] until 3 years. For 
this current analysis, we excluded all 30-day non-survi-
vors (N =  548), those who had previously received any 
organ transplant (N = 16) or had acquired immune defi-
ciency syndrome (AIDS) (N = 1). As a further explana-
tory analysis regarding potential survival bias, we present 
data from the entire FINNAKI cohort (n = 2901) without 
exclusions.
Data collection
We prospectively collected data on previous and pre-
sent medical status, patient demographics, ICU sever-
ity scores, presence of sepsis, possible risk factors for 
AKI, and existing comorbidities with study-specific case 
report form and from the database of the Finnish Inten-
sive Care Consortium (Tieto Ltd, Helsinki, Finland). Data 
regarding ICU treatment were collected until day 5. Finn-
ish Population Register Centre provided the survival data 
and the Finnish Registry for Kidney Diseases data on 
need for chronic dialysis at 3 years.
Definitions
 We measured plasma Cr concentration daily and urine 
output hourly and used the Kidney Disease: Improv-
ing Global Outcomes (KDIGO) [1] criteria to define and 
stage AKI, using both Cr and urine output criteria. As the 
baseline Cr, we used the latest value from previous year 
excluding the previous week. If it was unavailable, we 
estimated it by using the Modification of Diet in Renal 
Disease (MDRD) equation assuming a glomerular filtra-
tion rate (GFR) of 75  ml/min/1.73  m2 [12]. End-stage 
renal disease (ESRD) was defined by need for mainte-
nance dialysis at least for three months [13]. We defined 
sepsis according to the American College of Chest Physi-
cians/Society of Critical Care Medicine Consensus Con-
ference [14].
Cox model
We used Cox proportional hazards model to adjust for 
confounders related to survival at 3  years. We tested 
the validity of the proportional hazards assumption for 
Cox using the cox.zph method of the R survival package 
(hhtp://R-project.org) and found it to be valid in all mod-
els. We adjusted for gender, type of admission, pre-mor-
bid functional performance, presence of severe sepsis, or 
comorbidities (arteriosclerosis, chronic obstructive pul-
monary disease (COPD), CKD, diabetes mellitus, hyper-
tension, liver failure, malignancy, rheumatoid diseases, 
systolic heart failure, and thrombophilia), Simplified 
Acute Physiology Score (SAPS) II points without age and 
renal components, and use of vasoactive drugs in addi-
tion to the presence of AKI. These covariates were chosen 
based on their distribution between AKI and non-AKI 
groups. Patients with missing data were assumed not 
to have the chronic condition. We also performed three 
sensitivity analyses by excluding (1) patients with CKD, 
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(2) patients with AKI who did not receive RRT, (3) those 
with an estimated pre-admission Cr, or pre-existing 
CKD, or AKI stage 1. As a further explanatory analysis, 
time-stratified Cox models were generated as suggested 
[15].
Matching
As age and comorbidities are risk factors for both AKI [3, 
6] and increased long-term mortality [11], we performed 
a matched analysis between AKI and non-AKI patients. 
We matched patients 1:1 according to (1) age (caliper 
width  ±  5  years), (2) sex, (3) presence of severe sepsis 
in ICU, and (4) the logit of propensity score for develop-
ing AKI (caliper width 0.2 SD) at random and without 
replacement. The logistic regression model (presented in 
Additional file 1: Table S1) used to construct the propen-
sity score for AKI included variables previously reported 
to be associated with development of AKI [1, 3, 16] and 
the outcome as recommended [17]. We calculated stand-
ardized differences between the matched groups to assess 
the post-matching balance and considered standardized 
differences less than 10% indicative of good post-match-
ing balance [18].
Statistical analysis
We present continuous data as median with interquar-
tile range (IQR) and categorical data as absolute number 
and percentage. We used Chi-square test for categorical 
values and Mann–Whitney U test for continuous data 
in comparisons. We considered two-sided p value <0.05 
as significant. In the matched sample, we compared cat-
egorical data with the McNemar test. We calculated the 
95% CI for the difference in the 3-year mortality in the 
matched groups with Newcombe’s method [19]. We 
used SPSS version 23 (SPSS, Armonk, NY, USA) and R 
(http://R-project.org) for data analysis.
Results
Included patients
Altogether 2336 30-day survivors were included in the 
final analysis (study flowchart in Fig. 1). The incidence of 
AKI was 808/2336 (34.6%; 95% CI 32.7–36.5%), including 
378 (16.2%) patients with stage 1, 162 (6.9%) with stage 
2, and 268 (11.5%) with stage 3 AKI. During the first five 
days in ICU, 192 (8.3%; 95% CI 7.1–9.4%) patients com-
menced RRT. Table 1 presents characteristics of all study 
patients according to the presence of AKI.
Three‑year outcomes
The overall 3-year mortality was 479/2336 (20.5%; 95% 
CI 18.7–22.1%). Crude mortality among AKI patients 
was higher, 190 of 808 (23.5%, 95% CI 20.6–26.4%), 
compared to 289 of 1528 (18.9%; 95% CI 17.0–20.9%) 
in the non-AKI group (p  =  0.01). Figure  2 presents 
a Kaplan–Meier plot of unadjusted survival accord-
ing to the presence of AKI. Mortality was 84/378 
(22.2%) among stage 1, 39/162 (24.1%) among stage 2, 
and 67/268 (25.0%) among stage 3 AKI patients. After 
adjusting for age, comorbidities, and characteristics of 
ICU admission and treatment, AKI was not associated 
with an increased hazard for 3-year mortality (Table 2). 
Within 3  years, 20 of 808 AKI patients (2.5%; 95% CI 
1.4–3.6%) and 2 of 1526 non-AKI (0.1%; 95% CI −0.1 
to 0.3%) patients had developed ESRD (p < 0.001), with 
a relative risk (95% CI) of 18.9 (4.4–80.7), p  <  0.001. 
Among AKI patients who commenced RRT, 19 of 192 
developed ESRD (9.9%; 95% CI 5.7–14.1%).
Matched cohort
We found 662 matches to 662 AKI patients (81.9% of 
all 808 AKI patients). The groups were well balanced 
after matching (Table 3; Additional file 2: Figure 1). The 
3-year mortality among the matched AKI patients was 
136/662 (20.5%; 95% CI 17.5–23.6%) and among matched 
non-AKI patients 143/662 (21.6%; 95% CI 18.5–24.7%), 
p = 0.687. The absolute difference in mortality was −1.1 
(95% CI −5.5 to 3.3%). The crude 3-year mortality was 
54/146 (37.0%; 95% CI 29.2–44.8%) among AKI patients 
to whom we could not find a matched pair and 146/866 
(16.9%; 95% CI 14.4–19.4%) among unmatched patients 
without AKI. Unmatched AKI patients had worse 
Fig. 1 Study flowchart. AIDS acquired immune deficiency syndrome, 
AKI acute kidney injury, FINNAKI Finnish Acute Kidney Injury
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pre-morbid functional performance and more comor-
bidities than matched AKI patients (Additional file  1: 
Table S2). Figure  3 presents the Kaplan–Meier plot of 
the matched and unmatched patients according to AKI 
status.
Sensitivity analyses
After excluding patients with pre-existing CKD 
(N  =  134), the crude 3-year mortality was 156/727 
(21.5%; 95% CI 18.5–24.4%) among AKI patients and 
269/1475 (18.2%; 95% CI 16.2–20.2%) among non-AKI 
Table 1 Characteristics of  study patients (N =  2336) and  comparison between  patients with  and without  acute kidney 
injury
Categorical data are presented as an absolute number/count (percentage) and continuous data as median with IQR
AKI acute kidney injury, APACHE Acute Physiology and Chronic Health Evaluation, ICU intensive care unit, non-op non-operative, post-op postoperative, SAPS Simplified 
Acute Physiology Score
Characteristics Data available All
N = 2336
No AKI
N = 1528
AKI
N = 808
p value
Age (years) 2336 62.0 (49.0–72.0) 61.0 (47.0–71.0) 64.0 (53.0–73.8) <0.001
Gender (male) 2336 1479 (63.3) 951 (61.6) 538 (66.6) 0.019
Operative admission 2336 886 (37.9) 577 (37.8) 309 (38.2) 0.823
Emergency admission 2336 2007 (85.9) 1312 (85.9) 695 (86.0) 0.950
Pre‑morbid functional performance 2331 0.002
 Normal 1246 (53.5) 858 (56.2) 388 (48.2)
 Disabled to work but no need for assistance 803 (34.4) 500 (32.8) 303 (37.6)
 Some assistance required 216 (9.3) 131 (8.6) 85 (10.6)
 Totally dependent on assistance 66 (2.8) 37 (2.4) 29 (3.6)
APACHE diagnosis main groups 2336 <0.001
 Respiratory 264 (11.3) 178 (11.6) 86 (10.6)
 Metabolic 244 (10.4) 181 (11.8) 63 (7.8)
 Neurological 110 (4.7) 100 (6.5) 10 (1.2)
 Gastrointestinal, non‑op 139 (6.0) 81 (5.3) 58 (7.2)
 Gastrointestinal, post‑op 204 (8.7) 119 (7.8) 85 (10.5)
 Sepsis 126 (5.4) 61 (4.0) 65 (8.0)
 Cardiovascular, non‑op 244 (10.4) 155 (10.1) 89 (11.0)
 Cardiovascular, post‑op 400 (17.1) 240 (15.7) 160 (19.8)
 Trauma, non‑op 118 (5.1) 92 (6.0) 26 (3.2)
Arteriosclerosis 2336 279 (11.9) 158 (10.3) 121 (15.0) 0.001
Chronic kidney disease 2336 134 (5.7) 53 (3.5) 81 (10.0) <0.001
Chronic obstructive pulmonary disease 2336 203 (8.7) 127 (8.3) 76 (9.4) 0.396
Diabetes mellitus 2332 507 (21.7) 297 (19.5) 210 (26.0) <0.001
Hypertension 2336 1072 (45.9) 630 (41.2) 442 (54.7) <0.001
Chronic liver failure 2336 70 (3,0) 43 (2.8) 27 (3.3) 0.524
Malignancy 2200 63 (2.9) 44 (3.0) 19 (2.5) 0.504
Rheumatoid disease 2336 100 (4.3) 63 (4.1) 37 (4.6) 0.593
Systolic heart failure 2336 233 (10.0) 142 (9.3) 91 (11.3) 0.146
Thrombophilia 2336 125 (5.4) 81 (5.3) 44 (5.4) 0.923
Total number of comorbidities 2175 <0.001
 None 882 (37.8) 627 (41.0) 255 (31.6)
 One 627 (26.8) 432 (28.3) 195 (24.1)
 Two 478 (20.5) 288 (18.8) 190 (23.5)
 Three or more 349 (14.9) 181 (11.8) 168 (20.8)
Vasoactive drugs 2336 1419 (60.7) 810 (53.0) 609 (75.4) <0.001
Mechanical ventilation 2336 1540 (65.9) 975 (63.8) 565 (69.9) 0.003
Severe sepsis at ICU 2336 645 (27.6) 326 (21.3) 319 (39.5) <0.001
SAPS II 2336 34.0 (26.0–44.0) 32.0 (24.0–41.0) 39.0 (31.0–49.0) <0.001
SAPS II without age and renal points 2305 20.0 (13.0–27.0) 19.0 (13.0–27.0) 21.0 (15.0–28.0) 0.001
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patients (p  =  0.075). After adjustments, AKI was not 
associated with an increased hazard of time to death 
(HR 1.02; 95% CI 0.83–1.26, p = 0.831) (Additional file 1: 
Table S3).
When AKI patients commenced RRT (N = 192) were com-
pared to non-AKI patients, the crude 3-year mortality was 
47/192 (24.5%; 95% CI 18.4–30.6%) compared to 288/1525 
(18.9%; 95% CI 16.9–20.8%), p =  0.080. After adjusting for 
confounders, AKI necessitating RRT was not an independent 
risk factor for time to death during 3 years (HR 1.21; 95% CI 
0.86–1.70, p = 0.273) (Additional file 1: Table S4).
Finally, after excluding patients with an estimated base-
line Cr, pre-existing CKD, or stage 1 AKI (N  =  1222), 
crude mortality among AKI patients was 68/242 (28.1%; 
95% CI 22.4–33.8%) and among non-AKI patients 
188/872 (21.6%; 95% CI 18.8–24.3%), p  =  0.038. After 
adjusting for confounders, severe AKI was not signifi-
cantly associated with time to death in 3 years (HR 1.23; 
95% CI 0.91–1.65, p = 0.172) (Additional file 1: Table S5).
Explanatory analyses
In the whole FINNAKI cohort (n  =  2901) without 
30-day non-survivors excluded, 252 of the 1141 (22.0%) 
patients with AKI had treatment restrictions (do not 
resuscitate, do not escalate the level of treatment, with-
holding of intensive care) compared to 164 of the 1596 
(9.3%) patients without AKI, p < 0.001. When the whole 
cohort was included in a time-stratified model (Addi-
tional file  1: Table S6), AKI adjusted for confound-
ers was a significant risk factor for mortality in the 
time period from ICU admission to 30  days, but not 
thereafter.
Discussion
In this follow-up of the prospective, multicenter FIN-
NAKI study, we found that the crude 3-year mortality 
among 30-day survivors was significantly higher among 
AKI patients compared to those without AKI. However, 
after adjusting for confounders known to affect long-
term mortality, such as age and pre-existing comor-
bidities, AKI was not independently associated with 
decreased survival in the 3-year follow-up. The result was 
confirmed in a propensity-matched analysis and several 
sensitivity analyses.
While the role of AKI in increasing the short-term 
mortality is evident [3, 4, 6, 8], results regarding its role 
Fig. 2 Kaplan–Meier plot presenting the cumulative survival accord‑
ing to the presence of acute kidney injury. AKI acute kidney injury
Table 2 Multivariable adjusted Cox proportional hazards 
model for time to death during the 3-year follow-up
Model included 2305 patients and met the assumption of constant proportional 
hazards
Non-op non-operative, post-op postoperative, SAPS Simplified Acute Physiology 
Score
a Data from five patients were missing and assumed to be normal
b Patients with missing data were assumed not to have the chronic 
condition. Number of patients with imputed data according to comorbidity: 
arteriosclerosis 24, chronic kidney disease 9, chronic obstructive pulmonary 
disease 14, diabetes 4, hypertension 14, liver failure 24, malignancy 136, 
rheumatoid disease 18, systolic heart failure 21, and thrombophilia 11
c Data missing from 31 patients
Characteristic Hazard ratio (95% CI) p value
Age (years) 1.03 (1.03–1.04) <0.001
Gender (female) 0.82 (0.68–0.98) 0.047
Functional performancea (normal as 
the reference)
 Disabled to work but no need for 
assistance
1.65 (1.32–2.08) <0.001
 Some assistance required 2.65 (2.00–3.54) <0.001
 Totally dependent on assistance 3.48 (2.32–5.22) <0.001
Comorbiditiesb
  Arteriosclerosis 1.05 (0.81–1.37 0.703
  Chronic kidney disease 1.53 (1.23–2.07) 0.006
  Chronic obstructive pulmonary 
disease
1.63 (1.26–2.10) <0.001
  Diabetes mellitus 1.15 (0.92–1.43) 0.219
  Hypertension 0.85 (0.69–1.04) 0.125
  Chronic liver failure 2.90 (1.89–4.44) <0.001
  Malignancy 3.18 (2.18–4.62) <0.001
  Rheumatoid disease 1.87 (1.35–2.60) <0.001
  Systolic heart failure 0.96 (0.73–1.26) 0.774
  Thrombophilia 0.83 (0.57–1.20) 0.313
Operative admission 1.04 (0.84–1.30) 0.710
Emergency admission 1.65 (1.16–2.33) 0.005
SAPS without age and renal points 
(per point)c
1.00 (0.99–1.01) 0.646
Vasoactive drugs 1.12 (0.90–1.39) 0.296
Severe sepsis 1.09 (0.89–1.33) 0.422
Acute kidney injury 1.05 (0.86–1.27) 0.644
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in long-term mortality are conflicting. In contrast to our 
findings, AKI has been found to associate with increased 
1-year mortality among 30-day ICU survivors in a ret-
rospective database analysis [5]. However, the mortality 
among patients without AKI was notably lower than in 
our study that excluded low-risk patients with uncom-
plicated elective post-surgical admissions, while mortal-
ity among AKI patients was corresponding, which might 
explain the difference between the results. Another large 
retrospective analysis among post-surgical hospital survi-
vors found AKI defined by RIFLE Cr criteria to associate 
with decreased 10-year survival [20]. Both of these stud-
ies [5, 20] used the RIFLE Cr criterion to define AKI, and 
therefore, patients with oliguric AKI only were included 
in the control group. The long-term survival of patients 
with oliguric AKI without positive Cr criterion has been 
shown to be worse than of those without AKI but better 
compared to patients who fulfill both urine output and 
Cr criteria [21]. Therefore, the different methods of defin-
ing AKI may partly explain the controversy of these pre-
vious results to our study.
A large propensity-matched database analysis found 
AKI to associate with decreased survival among hospital-
ized patients after a median follow-up of 3 years [22]. In 
line with our findings, AKI was not a significant risk fac-
tor in the subgroup of critically ill patients [22]. Among 
Table 3 Characteristics of  the matched patients with  acute kidney injury (N =  662) and  their propensity-matched con-
trols (N = 662)
Categorical data are presented as an absolute number/count (percentage) and continuous data as median with IQR
AKI acute kidney injury, ICU intensive care unit, non-op non-operative, post-op postoperative, SAPS Simplified Acute Physiology Score
Characteristic Matched AKI patients Matched non‑AKI patients Standardized difference
Male gender 462/662 (69.8) 462/662 (69.8) 0
Age 63 [53–73] 63 [52–72] 1.6
Normal functional performance 332 (50.3) 342 (51.7) −2.4
Disabled to work but no need for assistance 244 (37.0) 242 (36.6) 0.62
Some assistance required 65 (9.8) 61 (9.2) 2.0
Totally dependent on assistance 19 (2.9) 17 (2.6) 1.8
Pre‑ICU risk factors for AKI
 Hypotension 151/662 (22.8) 146/622 (22.1) 1.6
 Cardiogenic shock 25/662 (3.8) 21/662 (3.2) 3.2
 Acute liver failure 12/662 (1.8) 12/662 (1.8) 0
 Colloids 220/662 (33.2) 215/662 (32.5) 1.4
 Diuretics 214/662 (32.3) 193/662 (29.2) 6.7
 Angiotensin‑converting‑enzyme inhibitors 186/662 (28.1) 169/662 (25.5) 5.9
 Radiocontrast dye 146/662 (22.1) 156/662 (23.6) −3.5
 Massive transfusion 24/662 (3.6) 20/662 (3.0) 3.4
 Non‑steroid anti‑inflammatory drugs 60/662 (9.1) 67/662 (10.1) −3.4
 Rhabdomyolysis 20/662 (3.0) 16/662 (2.4) 3.7
Chronic kidney disease 46/658 (7.0) 32/659 (4.9) 9.0
Hypertension 349/659 (53.0) 336/659 (51.0) 3.8
Arteriosclerosis 93/657 (14.2) 88/654 (13.5) 2.0
Chronic obstructive pulmonary disease 62/660 (9.4) 70/657 (10.7) −4.0
Heart failure 71/654 (10.9) 62/658 (9.4) 4.3
Chronic liver failure 20/658 (3.0) 15/654 (2.3) 4.4
Diabetes mellitus 160/661 (24.2) 163/660 (24.7) 2.8
Malignancy 14/619 (2.3) 18/627 (2.9) −3.9
Rheumatoid disease 25/658 (3.8) 31/657 (4.7) −4.5
Thrombophilia 38/661 (5.7) 39/658 (5.9) −0.86
Emergency admission 557/662 (84.1) 560/662 (84.6) −1.3
Operative admission 267/662 (40.3) 265/662 (40.0) 0.61
Severe sepsis 207/662 (31.3) 207/662 (31.3) 0
Mechanical ventilation 469/662 (70.8) 452/662 (68.3) 5.4
Vasoactive drugs 450/662 (68.9) 426/662 (64.4) 7.6
SAPS II without age and renal components 20.0 [14.0–27.0] 20.0 [14.0–27.0] 1.3
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cardiac surgical patients, the risk of death was higher at 
1  year than at three [23], and possibly the risk of death 
varies over time. Corresponding to our findings, AKI 
treated with RRT was not associated with an increased 
risk of 3-year all-cause mortality among 30-day survivors 
compared to matched hospitalized patients without AKI 
[10].
A plausible explanation to our findings is that post-
90-day mortality among general ICU patients is mainly 
determined by age and pre-existing comorbidities instead 
of characteristic of the acute illness [24]. In our previ-
ous sequentially matched analysis, we found the excess 
mortality attributable to AKI at 90 days to be 8.6% [16], 
which implies that AKI substantially affects the out-
comes of acute illness. Since AKI and long-term mortal-
ity share the same risk factors [3, 20, 24], the higher crude 
3-year mortality of AKI patients observed in the current 
analysis could be explained by higher age and number of 
comorbidities making the patients more susceptible for 
AKI as well as subsequent increased long-term mortal-
ity. Accordingly, instead of AKI, we found COPD, chronic 
liver failure, CKD, rheumatoid diseases, poor pre-morbid 
functional performance, and advanced age to associate 
with worse long-term outcome. Notably, poor pre-mor-
bid functional status and presence of malignancy were 
strongly associated with decreased survival at 3  years. 
Our results corroborate a Scottish study that found 
underlying CKD among patients commenced RRT to 
predict long-term mortality rather than severity of acute 
illness [25]. Finally, our results were robust to excluding 
patients with pre-existing CKD, those with estimated 
baseline Cr, and those AKI patients who did not receive 
RRT.
Albeit our analysis implies that AKI is not an independ-
ent risk factor for 3-year mortality among initial 30-day 
survivors, it does not mean that these patients would 
not be in an increased risk of other adverse outcomes. 
An episode of AKI has been shown to be associated with 
elevated risk of developing CKD and ESRD [7]. Addition-
ally, several animal models suggest that AKI can cause 
permanent damage on vasculature in kidney as well as 
outside of it [26]. Among hospitalized patients, de novo 
CKD developing after an episode of AKI has been shown 
to be an important explanatory factor for the increased 
long-term mortality of AKI survivors [22]. The risk of de 
novo CKD was found highest at three months after acute 
rise in Cr and to persist up to 5  years, although reduc-
ing in time [23]. The risk factors for developing de novo 
CKD after AKI included advanced age, pre-existing 
hypertension, and high Charlson comorbidity score [22], 
all of which are also risk factors for long-term mortality. 
Taken together, our analysis does not exclude the possi-
ble increase in post-3-year mortality due to potentially 
developing CKD and its subsequent complications such 
as increased cardiovascular mortality.
An obvious strength of our study was its multicenter 
nationwide setting, detailed prospective data collection, 
and a complete follow-up. Unlike other studies, with a 
comparably long study period including a selected cohort 
of patients [9, 10], our study included a heterogene-
ous cohort of critically ill patients, improving the exter-
nal validity of our results. However, this study has some 
important limitations. First, inherent to all observational 
studies, it is impossible to adjust for unmeasured fac-
tors. For example, we had no data of pre-existing neuro-
logical conditions. We included, however, the score for 
pre-morbid functional performance, which reflects also 
aspects of neurological problems, such as dementia. Sec-
ond, we did not have data about de novo CKD developing 
after an episode of AKI. However, the presence of CKD 
has been found to attenuate the mortality risk of AKI 
patients among hospitalized patients [22]. We found no 
difference between survival of AKI and non-AKI patients 
despite not adjusting for de novo CKD. Thus, we consider 
our findings representative and reliable. Third, the sam-
ple size of the matched cohort has approximately of 69% 
power to show a 5% difference assuming a 3-year mor-
tality of the non-AKI group of 21.6%, and therefore, the 
result of no significant difference must be interpreted 
with caution. Additionally, despite a statistically insignifi-
cant comparison, the number of patients in different sub-
groups, such as those treated with RRT, is inadequate to 
refute a clinically significant difference in 3-year mortal-
ity due to large CI (0.86–1.70).
Finally, when interpreting our results, a potential selec-
tion bias of AKI occurring in more severely ill patients 
Fig. 3 Kaplan–Meier plot presenting the cumulative survival accord‑
ing to matching and acute kidney injury status. The percentage in 
parenthesis presents the proportion of each group of the cohort of 
2336 patients. AKI acute kidney injury
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must be kept in mind. First, patients with AKI and 
greater illness severity more frequently had treatment 
restrictions, thus possibly forming the group of AKI sur-
vivors toward a healthier cohort. Second, as AKI gener-
ally occurs in the more severely ill, those who survive 
AKI may constitute a selected group of patients with 
lower risk of further adverse outcomes. Third, as encoun-
tered in other studies [10, 22], a small proportion of AKI 
patients (18.1%) in the current analysis was left without a 
match because severely ill patients without AKI could not 
be found. The survival curves of both the whole cohort 
after initial separation and the matched patients, how-
ever, are very collinear. Therefore, we consider our results 
to be informative in the case of corresponding baseline 
possibility of developing AKI and/or surviving intensive 
care regarding the outcome in the coming 3  years. We 
believe this result is of value, for example, when inform-
ing patients with AKI or their family.
Conclusion
Among critically ill patients surviving over 30  days, 
AKI was not an independent risk factor for mortality at 
3 years. AKI patients had higher crude 3-year mortality 
than non-AKI patients, but the difference was not robust 
for adjustments for a number of relevant confounders. 
Our findings imply that increased long-term mortality at 
3 years among patients with AKI who survive critical ill-
ness is not related to AKI per se, but rather to advanced 
age and pre-existing comorbidities.
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